We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

New Cutting-edge Cancer Imaging Network Is Established

New Cutting-edge Cancer Imaging Network Is Established

New Cutting-edge Cancer Imaging Network Is Established

New Cutting-edge Cancer Imaging Network Is Established

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "New Cutting-edge Cancer Imaging Network Is Established"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Nine world-leading medical imaging centres from across the UK will come together to form an integrated network for standardising and validating the use of cutting-edge imaging techniques in cancer treatment.

The National Cancer Imaging Translational Accelerator (NCITA) establishes infrastructure for validating and adopting cancer imaging biomarkers as decision-making tools in clinical trials and NHS practice.

Open access to world-class facilities

The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, will form part of this exciting new initiative, which will provide clinical researchers from across the UK with open access to world-class clinical imaging facilities and expertise, as well a repository data management service, artificial intelligence (AI) tools and ongoing training opportunities.

The NCITA consortium, through engagement with NHS Trusts, pharmaceutical companies, medical imaging and nuclear medicine companies as well as funding bodies and patient groups, aims to develop a robust and sustainable imaging biomarker certification process, to revolutionise the speed and accuracy of cancer diagnosis, tumour classification and patient response to treatment.

Professor Dow-Mu Koh, Professor of Functional Cancer Imaging at The Institute of Cancer Research, London, and Consultant Radiologist at The Royal Marsden NHS Foundation Trust, who co-leads the NCITA network, said:

“We are delighted to be part of NCITA and are working collaboratively to undertake a multicentre imaging study using whole body MRI in patients with multiple myeloma.”

World-leading medical imaging centres

The other institutions that make up NCITA are University College London, University of Manchester, University of Oxford, King’s College London, Imperial College London, Cambridge University, Newcastle University and University of Glasgow.

The initiative is funded by Cancer Research UK and will receive up to £10 million over five years and the lead investigators hope to expand and bring in new academic and industrial partnerships as NCITA develops.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.